(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 2.22% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Haemonetics's revenue in 2025 is $1,373,515,000.On average, 4 Wall Street analysts forecast HAE's revenue for 2026 to be $66,534,851,633, with the lowest HAE revenue forecast at $65,808,066,212, and the highest HAE revenue forecast at $66,892,693,103.
In 2027, HAE is forecast to generate $72,094,883,182 in revenue, with the lowest revenue forecast at $71,037,786,423 and the highest revenue forecast at $72,562,995,890.